Performance analysis of NeuroSense Therapeutics (NRSN)
Annual Return
Over the past 3 years, NRSN has had an average annual return of -20.08%, underperforming the benchmark SPY, which returned +19.62% annual.
Since Dec 9, 2021, NRSN has had an average annual return of -31.59%, underperforming the benchmark SPY, which returned +12.35% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.93% | -35.93% | +52.86% | -35.66% | -50.40% | -39.11% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +19.65% | -1.19% | -16.93% | +8.72% | +0.05% | -12.35% | -2.75% | -8.93% | |||||
| 2025 | -7.47% | -0.25% | -16.02% | +5.39% | +57.13% | +22.72% | -4.77% | -41.10% | +17.91% | -10.41% | +6.28% | -35.40% | -35.93% |
| 2024 | +59.24% | +41.60% | +2.83% | -25.82% | -20.02% | +3.70% | -32.14% | +17.12% | +42.71% | -1.59% | -21.59% | +22.42% | +52.86% |
| 2023 | +27.05% | +19.99% | -7.54% | +17.45% | -22.78% | -4.48% | -12.74% | -27.69% | -24.50% | -35.12% | +180.09% | -39.15% | -35.66% |
| 2022 | -19.92% | +31.99% | +52.69% | -57.69% | -16.07% | +139.71% | -44.67% | +4.28% | -8.20% | -10.63% | +7.50% | -29.06% | -50.40% |
| 2021 | -39.11% | -39.11% |
Drawdown analysis of NeuroSense Therapeutics (NRSN)
The maximum drawdown for the NRSN was -92.90%, occurring on Oct 30, 2023. This drawdown has not yet recovered.
The current NRSN drawdown is -88.76%.
Since Dec 9, 2021 NRSN has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.90% | Mar 21, 2022 | 405 | Oct 30, 2023 | Ongoing | Ongoing | Ongoing |
| -67.08% | Dec 9, 2021 | 64 | Mar 14, 2022 | 5 | Mar 21, 2022 | 69 |